{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:01:33Z","timestamp":1789740093319,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":79,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-06186-w","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:52:21Z","timestamp":1782870741000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u2018Aspirin versus ticagrelor for the management after coronary revascularization - a systematic review and meta\u2011analysis of randomised trials\u2019"],"prefix":"10.1186","volume":"26","author":[{"given":"Dhiraj Raj","family":"Regmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabita","family":"Regmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Upreti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"6186_CR1","unstructured":"Global burden of 288 causes of death. and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021 - The Lancet n.d. https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(24)00367-2\/fulltext. Accessed March 12, 2026."},{"key":"6186_CR2","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, et al. AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American heart association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023;148:e9\u2013119. https:\/\/doi.org\/10.1161\/CIR.0000000000001168.","journal-title":"Circulation"},{"key":"6186_CR3","unstructured":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization. A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation n.d. https:\/\/www.ahajournals.org\/doi\/10.1161\/CIR.0000000000001038. Accessed May 21, 2026."},{"key":"6186_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/j.1365-2125.2011.03943.x","volume":"72","author":"TD Warner","year":"2011","unstructured":"Warner TD, Nylander S, Whatling C. Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy. Br J Clin Pharmacol. 2011;72:619\u201333. https:\/\/doi.org\/10.1111\/j.1365-2125.2011.03943.x.","journal-title":"Br J Clin Pharmacol"},{"key":"6186_CR5","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","volume":"360","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354\u201362. https:\/\/doi.org\/10.1056\/NEJMoa0809171.","journal-title":"N Engl J Med"},{"key":"6186_CR6","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"PA Gurbel","year":"2009","unstructured":"Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the Antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease. Circulation. 2009;120:2577\u201385. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.912550.","journal-title":"Circulation"},{"key":"6186_CR7","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155\u201366. https:\/\/doi.org\/10.1056\/NEJMoa1409312.","journal-title":"N Engl J Med"},{"key":"6186_CR8","unstructured":"Ticagrelor alone versus dual antiplatelet therapy from. 1 month after drug-eluting coronary stenting | JACC n.d. https:\/\/www.jacc.org\/doi\/10.1016\/j.jacc.2019.08.1038 \u00a0. Accessed March 12, 2026."},{"key":"6186_CR9","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jama.2020.16167","volume":"324","author":"SC You","year":"2020","unstructured":"You SC, Rho Y, Bikdeli B, et al. Association of ticagrelor vs clopidogrel with net adverse clinical events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA. 2020;324:1640\u201350. https:\/\/doi.org\/10.1001\/jama.2020.16167.","journal-title":"JAMA"},{"key":"6186_CR10","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ccd.70410","volume":"107","author":"A Awashra","year":"2026","unstructured":"Awashra A, AbuBaha M, Emara A, et al. Reassessing PCI timing in high bleeding risk patients: evidence, strategies, and outcomes. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2026;107:780\u201394. https:\/\/doi.org\/10.1002\/ccd.70410.","journal-title":"Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv"},{"key":"6186_CR11","unstructured":"The PRISMA. 2020 statement: an updated guideline for reporting systematic reviews | The BMJ n.d. https:\/\/www.bmj.com\/content\/372\/bmj.n71. Accessed March 12, 2026."},{"key":"6186_CR12","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"6186_CR13","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/sim.1482","volume":"22","author":"G Knapp","year":"2003","unstructured":"Knapp G, Hartung J. Improved tests for a random effects meta-regression with a single covariate. Stat Med. 2003;22:2693\u2013710. https:\/\/doi.org\/10.1002\/sim.1482.","journal-title":"Stat Med"},{"key":"6186_CR14","unstructured":"Cochrane handbook for systematic reviews of interventions |. Cochrane n.d. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook. Accessed March 12, 2026."},{"key":"6186_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"key":"6186_CR16","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"P Vranckx","year":"2018","unstructured":"Vranckx P, Valgimigli M, J\u00fcni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392:940\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(18)31858-0.","journal-title":"Lancet"},{"key":"6186_CR17","doi-asserted-by":"crossref","unstructured":"Randomized trial of. ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial | European Heart Journal | Oxford Academic n.d. https:\/\/academic.oup.com\/eurheartj\/article-abstract\/40\/29\/2432\/5506732. Accessed March 12, 2026.","DOI":"10.1093\/eurheartj\/ehz185"},{"key":"6186_CR18","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1001\/jama.2018.3197","volume":"319","author":"Q Zhao","year":"2018","unstructured":"Zhao Q, Zhu Y, Xu Z, et al. Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial. JAMA. 2018;319:1677\u201386. https:\/\/doi.org\/10.1001\/jama.2018.3197.","journal-title":"JAMA"},{"key":"6186_CR19","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/jocs.16189","volume":"37","author":"A Kulik","year":"2022","unstructured":"Kulik A, Abreu AM, Boronat V, et al. Ticagrelor versus aspirin and vein graft patency after coronary bypass: a randomized trial. J Card Surg. 2022;37:563\u201370. https:\/\/doi.org\/10.1111\/jocs.16189.","journal-title":"J Card Surg"},{"key":"6186_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","volume":"82","author":"F Gragnano","year":"2023","unstructured":"Gragnano F, Cao D, Pirondini L, et al. P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events. JACC. 2023;82:89\u2013105. https:\/\/doi.org\/10.1016\/j.jacc.2023.04.051.","journal-title":"JACC"},{"key":"6186_CR21","unstructured":"Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention. The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial | Journal of the American Heart Association n.d. https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.120.016495. Accessed March 12, 2026."},{"key":"6186_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/cpt.1616","volume":"107","author":"L Traby","year":"2020","unstructured":"Traby L, Kollars M, Kaider A, et al. Differential effects of ticagrelor with or without aspirin on platelet reactivity and coagulation activation: a randomized trial in healthy volunteers. Clin Pharmacol Ther. 2020;107:415\u201322. https:\/\/doi.org\/10.1002\/cpt.1616.","journal-title":"Clin Pharmacol Ther"},{"key":"6186_CR23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/ehjcvp\/pvad032","volume":"9","author":"M Valgimigli","year":"2023","unstructured":"Valgimigli M, Aboyans V, Angiolillo D, et al. Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease. Eur Heart J Cardiovasc Pharmacother. 2023;9:462\u201396. https:\/\/doi.org\/10.1093\/ehjcvp\/pvad032.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"6186_CR24","doi-asserted-by":"publisher","first-page":"oeac019","DOI":"10.1093\/ehjopen\/oeac019","volume":"2","author":"D Aggarwal","year":"2022","unstructured":"Aggarwal D, Bhatia K, Chunawala ZS, et al. P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. Eur Heart J Open. 2022;2:oeac019. https:\/\/doi.org\/10.1093\/ehjopen\/oeac019.","journal-title":"Eur Heart J Open"},{"key":"6186_CR25","doi-asserted-by":"publisher","first-page":"e377","DOI":"10.4244\/EIJ-D-21-00870","volume":"18","author":"M Ono","year":"2022","unstructured":"Ono M, Hara H, Kawashima H, et al. Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the global leaders trial. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2022;18:e377\u201388. https:\/\/doi.org\/10.4244\/EIJ-D-21-00870.","journal-title":"EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol"},{"key":"6186_CR26","doi-asserted-by":"publisher","first-page":"e075707","DOI":"10.1136\/bmj-2023-075707","volume":"385","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Zhang W, Dimagli A, et al. Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised DACAB trial. BMJ. 2024;385:e075707. https:\/\/doi.org\/10.1136\/bmj-2023-075707.","journal-title":"BMJ"},{"key":"6186_CR27","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1016\/j.jacc.2020.03.011","volume":"75","author":"G Dangas","year":"2020","unstructured":"Dangas G, Baber U, Sharma S, et al. Ticagrelor with or without aspirin after complex PCI. J Am Coll Cardiol. 2020;75:2414\u201324. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.011.","journal-title":"J Am Coll Cardiol"},{"key":"6186_CR28","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.athoracsur.2022.10.040","volume":"115","author":"H-H Kim","year":"2023","unstructured":"Kim H-H, Yoo K-J, Youn Y-N. A randomized trial of clopidogrel vs ticagrelor after off-pump coronary bypass. Ann Thorac Surg. 2023;115:1127\u201334. https:\/\/doi.org\/10.1016\/j.athoracsur.2022.10.040.","journal-title":"Ann Thorac Surg"},{"key":"6186_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.amjcard.2025.07.010","volume":"256","author":"O Elkoumi","year":"2025","unstructured":"Elkoumi O, Elkoumi A, Elbairy MK, et al. Impact of statins on mortality and cardiovascular outcomes in dialysis patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Am J Cardiol. 2025;256:49\u201359. https:\/\/doi.org\/10.1016\/j.amjcard.2025.07.010.","journal-title":"Am J Cardiol"},{"key":"6186_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40256-026-00789-6","volume":"26","author":"A Awashra","year":"2026","unstructured":"Awashra A, Emara A, Amin AM, et al. Beta-blockers after myocardial infarction without reduced ejection fraction: a meta-analysis of kaplan-meier reconstructed individual patient data. Am J Cardiovasc Drugs Drugs Devices Interv. 2026;26:345\u201358. https:\/\/doi.org\/10.1007\/s40256-026-00789-6.","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-06186-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06186-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-06186-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:02:35Z","timestamp":1789736555000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-06186-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6186"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-06186-w","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval and informed consent were not required as this study is a systematic review and meta-analysis of previously published data.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"811"}}